Evelo Biosciences Stock Net Income
| EVLO Stock | USD 0.0001 0.0001 50.00% |
As of the 7th of February, Evelo Biosciences shows the Mean Deviation of 12.71, standard deviation of 51.55, and Variance of 2657.02. Evelo Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Evelo Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Evelo Biosciences' valuation are provided below:Evelo Biosciences does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Evelo |
Evelo Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Evelo Biosciences' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Evelo Biosciences.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Evelo Biosciences on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Evelo Biosciences or generate 0.0% return on investment in Evelo Biosciences over 90 days. Evelo Biosciences is related to or competes with HST Global. Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammator... More
Evelo Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Evelo Biosciences' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Evelo Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0526 | |||
| Maximum Drawdown | 460.0 | |||
| Value At Risk | (50.00) |
Evelo Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evelo Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Evelo Biosciences' standard deviation. In reality, there are many statistical measures that can use Evelo Biosciences historical prices to predict the future Evelo Biosciences' volatility.| Risk Adjusted Performance | 0.0537 | |||
| Jensen Alpha | 2.39 | |||
| Total Risk Alpha | (2.30) | |||
| Treynor Ratio | 0.5527 |
Evelo Biosciences February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0537 | |||
| Market Risk Adjusted Performance | 0.5627 | |||
| Mean Deviation | 12.71 | |||
| Coefficient Of Variation | 1838.95 | |||
| Standard Deviation | 51.55 | |||
| Variance | 2657.02 | |||
| Information Ratio | 0.0526 | |||
| Jensen Alpha | 2.39 | |||
| Total Risk Alpha | (2.30) | |||
| Treynor Ratio | 0.5527 | |||
| Maximum Drawdown | 460.0 | |||
| Value At Risk | (50.00) | |||
| Skewness | 7.17 | |||
| Kurtosis | 56.46 |
Evelo Biosciences Backtested Returns
Evelo Biosciences is out of control given 3 months investment horizon. Evelo Biosciences secures Sharpe Ratio (or Efficiency) of 0.0622, which denotes the company had a 0.0622 % return per unit of risk over the last 3 months. We were able to break down and interpolate nineteen different technical indicators, which can help you to evaluate if expected returns of 3.31% are justified by taking the suggested risk. Use Evelo Biosciences Mean Deviation of 12.71, variance of 2657.02, and Standard Deviation of 51.55 to evaluate company specific risk that cannot be diversified away. Evelo Biosciences holds a performance score of 4 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 5.05, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evelo Biosciences will likely underperform. Use Evelo Biosciences mean deviation, jensen alpha, as well as the relationship between the Jensen Alpha and rate of daily change , to analyze future returns on Evelo Biosciences.
Auto-correlation | 0.40 |
Average predictability
Evelo Biosciences has average predictability. Overlapping area represents the amount of predictability between Evelo Biosciences time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Evelo Biosciences price movement. The serial correlation of 0.4 indicates that just about 40.0% of current Evelo Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.4 | |
| Spearman Rank Test | 0.7 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Evelo Biosciences reported net income of (114.53 Million). This is 133.56% lower than that of the Biotechnology sector and 263.5% lower than that of the Health Care industry. The net income for all United States stocks is 120.06% higher than that of the company.
Evelo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evelo Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Evelo Biosciences could also be used in its relative valuation, which is a method of valuing Evelo Biosciences by comparing valuation metrics of similar companies.Evelo Biosciences is currently under evaluation in net income category among its peers.
Evelo Fundamentals
| Return On Equity | -62.33 | |||
| Return On Asset | -0.83 | |||
| Current Valuation | 23.69 M | |||
| Shares Outstanding | 18.93 M | |||
| Shares Owned By Insiders | 0.23 % | |||
| Shares Owned By Institutions | 83.13 % | |||
| Number Of Shares Shorted | 430.1 K | |||
| Price To Earning | (4.19) X | |||
| Price To Book | 3.51 X | |||
| EBITDA | (108.41 M) | |||
| Net Income | (114.53 M) | |||
| Cash And Equivalents | 92.01 M | |||
| Cash Per Share | 0.85 X | |||
| Total Debt | 51.14 M | |||
| Debt To Equity | 1.55 % | |||
| Current Ratio | 4.53 X | |||
| Book Value Per Share | (1.42) X | |||
| Cash Flow From Operations | (101.23 M) | |||
| Short Ratio | 0.42 X | |||
| Earnings Per Share | (15.64) X | |||
| Target Price | 10.0 | |||
| Number Of Employees | 66 | |||
| Beta | 1.74 | |||
| Market Capitalization | 7 M | |||
| Total Asset | 64.44 M | |||
| Retained Earnings | (529.22 M) | |||
| Working Capital | 39.18 M | |||
| Current Asset | 49.29 M | |||
| Current Liabilities | 4.32 M | |||
| Z Score | -16.24 | |||
| Net Asset | 64.44 M |
About Evelo Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evelo Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Evelo Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evelo Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evelo Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Evelo Pink Sheet
| 0.59 | MCD | McDonalds Earnings Call This Week | PairCorr |
| 0.55 | CSCO | Cisco Systems Earnings Call This Week | PairCorr |
| 0.48 | KO | Coca Cola Aggressive Push | PairCorr |
| 0.47 | WMT | Walmart Common Stock Aggressive Push | PairCorr |
| 0.45 | JNJ | Johnson Johnson | PairCorr |
The ability to find closely correlated positions to Evelo Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evelo Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evelo Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evelo Biosciences to buy it.
The correlation of Evelo Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evelo Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evelo Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evelo Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Evelo Pink Sheet
Evelo Biosciences financial ratios help investors to determine whether Evelo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evelo with respect to the benefits of owning Evelo Biosciences security.